@article{b1fcd73f32fb447ab0c6a4bf06884b63,
title = "Structure-based virtual screening discovers potent and selective adenosine A1 receptor antagonists",
abstract = "Development of subtype-selective leads is essential in drug discovery campaigns targeting G protein-coupled receptors (GPCRs). Herein, a structure-based virtual screening approach to rationally design subtype-selective ligands was applied to the A1 and A2A adenosine receptors (A1R and A2AR). Crystal structures of these closely related subtypes revealed a non-conserved subpocket in the binding sites that could be exploited to identify A1R selective ligands. A library of 4.6 million compounds was screened computationally against both receptors using molecular docking and 20 A1R selective ligands were predicted. Of these, seven antagonized the A1R with micromolar activities and several compounds displayed slight selectivity for this subtype. Twenty-seven analogs of two discovered scaffolds were designed, resulting in antagonists with nanomolar potency and up to 76-fold A1R-selectivity. Our results show the potential of structure-based virtual screening to guide discovery and optimization of subtype-selective ligands, which could facilitate the development of safer drugs.",
keywords = "Computer-aided drug design, G protein-coupled receptor, Molecular docking, Selectivity",
author = "Pierre Matricon and Nguyen, {Anh TN} and Vo, {Duc Duy} and Baltos, {Jo Anne} and Mariama Jaiteh and Andreas Luttens and Stefanie Kampen and Arthur Christopoulos and Jan Kihlberg and May, {Lauren Therese} and Jens Carlsson",
note = "Funding Information: J.C. received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement: 715052 ), the Swedish Research Council (VR, grants: 2017-4676 and 2021-4186 ), and the Swedish Strategic Research Program eSSENCE . This work was also supported by the National Health and Medical Research Council of Australia (NHMRC) project grants: APP1145420 (L T M., A.C.), APP1147291 (L.T.M.). L.T.M. is an Australian National Heart Foundation Future Leaders Fellow. The computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at NSC and UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018–05973 . This study made use of the NMR Uppsala infrastructure, which is funded by the Department of Chemistry—BMC and the Disciplinary Domain of Medicine and Pharmacy. We thank OpenEye Scientific Software for the use of OEToolKits at no cost. Funding Information: J.C. received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement: 715052), the Swedish Research Council (VR, grants: 2017-4676 and 2021-4186), and the Swedish Strategic Research Program eSSENCE. This work was also supported by the National Health and Medical Research Council of Australia (NHMRC) project grants: APP1145420 (L T M. A.C.), APP1147291 (L.T.M.). L.T.M. is an Australian National Heart Foundation Future Leaders Fellow. The computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at NSC and UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018–05973. This study made use of the NMR Uppsala infrastructure, which is funded by the Department of Chemistry—BMC and the Disciplinary Domain of Medicine and Pharmacy. We thank OpenEye Scientific Software for the use of OEToolKits at no cost. Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
month = sep,
day = "5",
doi = "10.1016/j.ejmech.2023.115419",
language = "English",
volume = "257",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier",
}